Ancora Holdings Builds $200M Stake in Warner Bros Discovery, Targets Netflix Asset Sale Plan 
Petrobras Posts Record Oil Exports as Production Surge Fuels Global Expansion 
Moderna Stock Drops After FDA Declines Review of mRNA Flu Vaccine 
SMIC Shares Slide Despite Strong AI-Driven Earnings as Margin Pressure Looms 
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision 
ByteDance Advances AI Chip Development With Samsung Manufacturing Talks 
Air New Zealand Cabin Crew Strike Set for February 12–13 Amid Failed Talks 
Trump Administration Plans Chip Tariff Exemptions for Big Tech Amid AI Data Center Push 
Amazon Explores AI Content Marketplace With Media Publishers 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Russia Signals Further Restrictions on Telegram Amid Ongoing Regulatory Disputes 
Macquarie Group Shares Jump as Third-Quarter Trading Conditions Improve Across Key Units 
Cloudflare Forecasts Strong Revenue Growth as AI Fuels Cloud Services Demand 
FDA Rejects Review of Moderna’s Flu Vaccine Application, Shares Slide 
CBA Shares Surge After Record Half-Year Profit as Rate Outlook Improves 
AST SpaceMobile Joins MSCI ACWI Index as Largest New Addition, Boosting Market Visibility 
Canadian Airlines Suspend Cuba Flights Amid Jet Fuel Shortage and U.S. Sanctions 
SAN FRANCISCO, April 06, 2018 -- Hagens Berman Sobol Shapiro LLP reminds investors in MiMedx Group, Inc. (NASDAQ:MDXG) of the April 25, 2018 Lead Plaintiff deadline in the pending securities class action. If you purchased or otherwise acquired securities of MiMedx between March 7, 2013 and February 21, 2018 and suffered losses contact Hagens Berman Sobol Shapiro LLP. For more information visit:
https://www.hbsslaw.com/cases/MDXG
or contact Reed Kathrein, who is leading the firm’s investigation, by calling 510-725-3000 or emailing
On February 20, 2018, MiMedx postponed release of its fourth quarter and fiscal year 2017 financial results. Defendants explained “[t]he Audit Committee of MiMedx’s Board of Directors has engaged independent legal and accounting advisors to conduct an internal investigation into current and prior-period matters relating to allegations regarding certain sales and distribution practices at the Company” and “Company executives are also reviewing, among other items, the accounting treatment of certain distributor contracts[.]”
This news drove the price of MiMedx shares down $5.72, or nearly 40%, to close at $8.75 on February 20, 2018.
Then, Reuters reported federal authorities are investigating whether MiMedx overcharged the government for its tissue-repair products and whether it improperly booked sales of products that hadn’t been ordered, a practice known as channel stuffing.
“We’re focused on Defendants’ previous denials of improper accounting that, if false, damaged investors and on whether MiMedx submitted false claims to the Federal government,” said Hagens Berman partner Reed Kathrein.
Whistleblowers: Persons with non-public information regarding MiMedx should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 510-725-3000 or email [email protected].
About Hagens Berman
Hagens Berman is a national investor-rights law firm headquartered in Seattle, Washington with 70+ attorneys in 11 offices across the country. The Firm represents investors, whistleblowers, workers and consumers in complex litigation. More about the firm and its successes can be found at www.hbsslaw.com. For the latest news visit our newsroom or follow us on Twitter at @classactionlaw.
Contact:
Reed Kathrein, 510-725-3000
